Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt+), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)
暂无分享,去创建一个
P-C. Yang | Y. Cheng | H. Murakami | M. Orlando | J. Kim | K. Nakagawa | R. Hozak | T. Nguyen | S. Enatsu | T. Puri | J. Kang | Xin Wang | J. He | Joo-sung Yang | J. He | T. Nguyen